Opinion|Videos|October 18, 2024
Biomarker Discovery and Exploration for SCLC
Key Takeaways
- Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer.
- Testing is usually incorporated at diagnosis or during disease progression to guide therapeutic decisions.
Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring the existing unmet needs in biomarker testing for SCLC and potential strategies to address and overcome these challenges in the future.
Advertisement
Episodes in this series
What is the role of biomarker testing in your patients with small cell lung cancer (SCLC)? When in their treatment journey do you incorporate it?
What are the current unmet needs with biomarker testing in SCLC, and how can they be addressed and overcome in the future?
Advertisement
Related to this article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Advertisement
Advertisement